Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia

Morie A. Gertz

DOI: https://doi.org/10.1016/j.hoc.2021.11.001

IF: 2.861

2022-04-01

Hematology/Oncology Clinics of North America

Abstract:•Cold agglutinin disease represents a direct antiglobulin-positive hemolytic anemia.•In cold agglutinin disease, there is a low-grade lymphoplasmacytic clonal process in the bone marrow that produces a monoclonal IgM protein that fixes complement to the red cell and results in extravascular hemolysis.•Current therapies focus on the reduction of synthesis of the monoclonal IgM protein using rituximab, bortezomib, or bendamustine alone or in combination.•Emerging therapy designed to block complementCold agglutinin disease represents a direct antiglobulin-positive hemolytic anemia.In cold agglutinin disease, there is a low-grade lymphoplasmacytic clonal process in the bone marrow that produces a monoclonal IgM protein that fixes complement to the red cell and results in extravascular hemolysis.Current therapies focus on the reduction of synthesis of the monoclonal IgM protein using rituximab, bortezomib, or bendamustine alone or in combination.Emerging therapy designed to block complement